300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 12.52
−0.24%Oct 28, 2026, 23:50 UTC
Tianxiang Investment Consulting reported that technology and pharmaceutical companies dominated the top 50 stocks newly added to mutual funds’ major holdings by the end of the third quarter of 2026.
Source:Oct 16, 2026, 10:52 UTC
Kangtai Biological Products said it recently obtained a property ownership certificate for the 20,383.3-square-meter industrial land parcel in Xili, Nanshan District, Shenzhen, acquired for its Baiwangxin emergency engineering construction project.
Source:Oct 16, 2026, 10:51 UTC
Jiangxi Qingping Garden Art Co., Ltd. sued Kangtai Biological Technology Co., Ltd. and its wholly owned subsidiary Shenzhen Xintaikang Biotechnology Co., Ltd. over an engineering contract dispute and sought asset preservation, resulting in a freeze of RMB 43.0577 million in Kangtai's basic bank account.
Source:Oct 12, 2026, 08:27 UTC
Kangtai Biological said its wholly owned subsidiary Beijing Minhai Biotechnology began a Phase I clinical trial of an acellular DTaP component combination vaccine and enrolled its first participant.
Source:Aug 21, 2026, 12:35 UTC
Kangtai Biological Products announced an interim dividend for the first half of 2026 of 0.27 yuan per 10 shares (pre-tax), totaling 30 million yuan, representing 59.85% of the period's net profit.
Source:Aug 21, 2026, 12:35 UTC
Kangtai Biological Products announced its first-half 2026 results: revenue of 1.273 billion yuan, down 8.55% year-on-year; net profit attributable to shareholders of 50.3861 million yuan, up 34.25% year-on-year.
Source:Jul 2, 2026, 08:17 UTC
Kangtai Biological's vice president Gan Jianhui resigned due to personal health reasons.
Source: